On Nov. 5, 2020, RELIEF THERAPEUTICS and NeuroRx announced that the independent Data Monitoring Committee (DMC) voted unanimously that NCT 04311697 should continue as planned to its full enrollment of 165 patients.

Specifically, the committee identified no safety concerns and viewed the study as capable of reaching its prespecified endpoint in potentially proving that RLF-100ﾙ (aviptadil) is superior to placebo in achieving recovery from respiratory failure in patients with critical COVID-19 at a statistically significant level.